HANGZHOU ZHONGMEI
GenericsHANGZHOU ZHONGMEI is a generic drug manufacturer focused on Metabolic, Dermatology, Oncology.
HANGZHOU ZHONGMEI at a Glance
- Growing R&D activity with 37 trials in last 2 years
- Fast trial execution (8 months median completion)
HANGZHOU ZHONGMEI's Key Drugs
HANGZHOU ZHONGMEI's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
HANGZHOU ZHONGMEI's Recent FDA Approvals
HANGZHOU ZHONGMEI secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HANGZHOU ZHONGMEI's Therapeutic Areas
HANGZHOU ZHONGMEI's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HANGZHOU ZHONGMEI's Top Competitors
HANGZHOU ZHONGMEI's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HANGZHOU ZHONGMEI Pipeline Snapshot
HANGZHOU ZHONGMEI has 38 active clinical programs from ClinicalTrials.gov — 14 Phase 3, 5 Phase 2 and 19 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/12 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-08-18
- Latest
- 2025-07-18
- Applications
- 6
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges